(R)-1-(5-fluoro-2-methoxyphenyl)ethanol | 1346818-41-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (R)-1-(5-fluoro-2-methoxyphenyl)ethanol
• 英文别名: (R)-1-(5-Fluoro-2-methoxy-phenyl)-ethanol；(1R)-1-(5-fluoro-2-methoxyphenyl)ethanol
• CAS: 1346818-41-4
• 化学式: C₉H₁₁FO₂
• 分子量: 170.184
• InChiKey: VLBOHPCLXJIASU-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-氨基-4-溴-6-氯哒嗪 、 (R)-1-(5-fluoro-2-methoxyphenyl)ethanol 在 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以54%的产率得到6-chloro-4-[(R)-1-(5-fluoro-2-methoxyphenyl)ethoxy]pyridazin-3-ylamine
  参考文献：
  名称：

  [EN] HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS
  [FR] DÉRIVÉS HÉTÉROCYCLIQUES DESTINÉS AU TRAITEMENT DE MALADIES

  摘要：

  公开号：

  WO2011138751A3
• 作为产物：
  描述：

  5’-氟-2’-甲氧基苯乙酮 在 (+)-二异松蒎基氯硼烷 作用下， 以63%的产率得到(R)-1-(5-fluoro-2-methoxyphenyl)ethanol
  参考文献：
  名称：

  [EN] HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS
  [FR] DÉRIVÉS HÉTÉROCYCLIQUES DESTINÉS AU TRAITEMENT DE MALADIES

  摘要：

  公开号：

  WO2011138751A3

文献信息

• HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES
  申请人：Bunnage Mark Edward

  公开号：US20130196952A1

  公开（公告）日：2013-08-01

  The invention relates to compounds of Formula (1) and to processes for the preparation of intermediates used in the preparation of compositions containing and the uses of such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

  本发明涉及式（1）的化合物，以及用于制备含有这些衍生物的组合物的中间体的制备过程和使用。根据本发明的化合物在许多与ALK蛋白有关或抑制ALK活性可能产生益处的疾病中非常有用，特别是用于治疗由突变的EML4-ALK融合蛋白介导的癌症。
• Alkoxy-substituted 2-aminopyridines as ALK inhibitors
  申请人：Bunnage Mark Edward

  公开号：US08916593B2

  公开（公告）日：2014-12-23

  The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

  本发明涉及式（1）的化合物以及制备、制备中间体、含有和使用这些衍生物的组合物的过程。根据本发明的化合物在许多涉及ALK蛋白质或抑制ALK活性可能产生益处的疾病中有用，特别是用于治疗由突变的EML4-ALK融合蛋白介导的癌症。
• Synthesis and Catalytic Applications of an Extended Range of Tethered Ruthenium(II)/η⁶-Arene/Diamine Complexes
  作者：Roy Hodgkinson、Václav Jurčík、Antonio Zanotti-Gerosa、Hans Günter Nedden、Andrew Blackaby、Guy J. Clarkson、Martin Wills

  DOI：10.1021/om500788t

  日期：2014.10.13

  A series of novel enantiopure Ru(II) complexes containing a chiral diamine and eta(6)-arene connected by a tethering group have been prepared and were evaluated in the asymmetric reductions of a range of ketones. Changes to the level of steric hindrance and the addition of an electron withdrawing functionality on the sulfonyl group have a significant effect on the reactivity and enantioselectivity of the catalysts.
• Synthesis of Aryl Ethers via a Sulfonyl Transfer Reaction
  作者：Neal W. Sach、Daniel T. Richter、Stephan Cripps、Michelle Tran-Dubé、Huichun Zhu、Buwen Huang、Jean Cui、Scott C. Sutton

  DOI：10.1021/ol301615z

  日期：2012.8.3

  A general synthesis of aryl ethers from primary and secondary alcohols and aryl mesylates is presented. The reaction proceeds via a sulfonyl-transfer mechanism. In this paper, we compare the sulfonyl transfer reaction to Mitsunobu ether formation. The reaction can be employed in a multistep synthesis where the aryl mesylate is used as a phenol protecting group and then as an activating group for ether formation. This protecting/activating group strategy is demonstrated using raloxifene as the target.
• HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS
  申请人：Pfizer Inc.

  公开号：EP2566858A2

  公开（公告）日：2013-03-13